£3.3m raised ✔️ Major Spanish production site acquired ✔️
In this week's newsletter, read all about the latest target we've smashed in our crowdfunder, our latest major acquisition, and all the usual updates from patients and the Grow team! 💚
A newsletter all about cannabis medicines, that offers patient and business perspectives written by the team at Grow.
🌱 This week, in the world of cannabis medicine:
→ Investor intro: Meet one of our investors - Dean!
→ Grow updates
→ Patient perspectives: Tristan’s story
Hi everyone - great to meet some budding investors! 👋
I’m Dean, an investor and non-executive director at Grow and the person introducing this week’s newsletter. It’s been another incredible week for Grow’s crowdfund campaign and from an investor perspective, it is really exciting to watch as the company goes from strength to strength.
One of the primary reasons I invested in Grow was because of the incredible focus they place on engaging and listening to the community of people they have supporting their work. It’s brilliant to be part of a shareholder group united under one vision.
Being part of the Grow journey is one of my most rewarding investments so far. I have spent over five years looking at the global cannabis space as both an investor and advisor and I am a strong believer in both the investment case of this incredible industry and of the power of medical cannabis to improve people's lives. ‘Social investing’ with Grow was an easy decision…help others first and help yourself financially later!
Scroll down to get all the latest updates and read this week’s gripping patient story on how cannabis medicines changed their life.
→ 📰 In the News: Our CEO Ben spoke to The Telegraph this week about our major acquisition of Sanoid Isolates and their facilities in Spain! 🏭 The move helps Grow become a fully integrated cannabis production, R&D, and distribution company. The news was also covered in BDaily and Proactive Investors!
And not only that… we announced we’re partnering with ALT (Advanced Liquid Technology) to launch and market their liquid medical cannabis products across Europe. 🙌
→ 🚨 Crowdfund update: We’ve hit the £3.3m mark in our crowdfunder! 🥳 A huge thank you to the 350+ investors who have already gotten involved so far and joined our ever-expanding socially-conscious shareholder community (and for anyone who still wants to, you know the drill - you can invest here)!
“Back in 2019, I underwent a second surgery for an aortic valve replacement on the left-hand artery of the heart. And, whilst my heart is now good for another 30 years, I still suffer from terrible insomnia due to pain in my left-hand side.
“A friend told me about cannabis medicines around 16 months ago and I applied to a well-known clinic, where my case went to the weekly board meeting and I was accepted 😀!
“The last 15 months have been a rollercoaster but I’ve now found what works best for me - the mid-range THC based sativa is perfect for me as a heart patient. I find myself being more active - hiking for 45 minutes a day and even doing a few reps on my 5 kilo weights.
“My life has changed for the better and I truly believe everyone eligible should be on a [cannabis medicine] prescription!”
Tips to Grow 💪
🌱 Get daily news, community chat & crowdfunding updates on Twitter & LinkedIn.
🌱 Want to knowledge share with us? Drop us a note!
🌱 Share with your pals and tell them about the massive positive potential of cannabis medicines.
Thanks for reading, see you next week 👋👋👋
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Seedrs does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Seedrs, through email or any other medium, should be construed as an investment recommendation.
This email has been approved as a financial promotion by Seedrs Limited.